Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Integra Lifesciences (IART) and KalVista Pharmaceuticals (KALV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), Integra Lifesciences (IART – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments.

EyePoint Pharmaceuticals (EYPT)

Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on EyePoint Pharmaceuticals yesterday and set a price target of $33.00. The company’s shares closed last Tuesday at $9.20.

According to TipRanks.com, Kusy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.1% and a 30.2% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Apellis Pharmaceuticals, and Iovance Biotherapeutics.

EyePoint Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.80.

See today’s best-performing stocks on TipRanks >>

Integra Lifesciences (IART)

Integra Lifesciences received a Buy rating and a $53.00 price target from Jefferies analyst Matthew Taylor yesterday. The company’s shares closed last Tuesday at $41.30.

According to TipRanks.com, Taylor is a 5-star analyst with an average return of 12.1% and a 65.0% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Boston Scientific, and Becton Dickinson.

Currently, the analyst consensus on Integra Lifesciences is a Hold with an average price target of $46.78.

KalVista Pharmaceuticals (KALV)

SVB Securities analyst Joseph Schwartz maintained a Buy rating on KalVista Pharmaceuticals on July 7 and set a price target of $20.00. The company’s shares closed last Tuesday at $9.80.

According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.9% and a 32.9% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceutical.

Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $21.00, which is a 101.3% upside from current levels. In a report issued on July 7, Jefferies also maintained a Buy rating on the stock with a $26.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EYPT:

• Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023
• EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
• EyePoint appoints Duker as CEO, Lurker as Executive Vice Chair of the Board
• Biotech Alert: Searches spiking for these stocks today
• EyePoint named a top pick heading into 2H23 at Cantor Fitzgerald